

Table 1. Reviewed articles by category.

Category	Authors	Title	Journal Name
Automated perimetry	Rao HL, Yadav RK, Begum VU, et al. ¹	Role of visual field reliability indices in ruling out glaucoma.	JAMA Ophthalmol.
	Musch DC, Gillespie BW, Palmberg PF, et al. ²	Visual field improvement in the collaborative initial glaucoma treatment study.	Am. J. Ophthalmol.
	Liu S, Yu M, Weinreb RN, et al. ³	Frequency doubling technology perimetry for detection of visual field progression in glaucoma: a pointwise linear regression analysis.	Invest. Ophthalmol. Vis. Sci.
	Meira-Freitas D, Tatham AJ, Lisboa R, et al. ⁴	Predicting progression of glaucoma from rates of frequency doubling technology perimetry change.	Ophthalmology.
	Prokosch V, Eter N. ⁵	Correlation between early retinal nerve fiber layer loss and visual field loss determined by three different perimetric strategies: white-on-white, frequency-doubling, or flicker-defined form perimetry.	Graefes Arch Clin Exp Ophthalmol.
Optic nerve head and imaging	Hata M, Miyamoto K, Oishi A, et al. ⁶	Comparison of Optic Disc Morphology of Optic Nerve Atrophy between Compressive Optic Neuropathy and Glaucomatous Optic Neuropathy.	PloS One.
	Danesh-Meyer HV, Yap J, Frampton C, Savino PJ. ⁷	Differentiation of compressive from glaucomatous optic neuropathy with spectral-domain optical coherence tomography.	Ophthalmology.
	Akkaya S, Can E, Oztürk F. ⁸	Comparison of Optic Nerve Head Topographic Parameters in Patients	J. Glaucoma.

**Structure and
function**

Xu G, Weinreb RN, Leung CKS. ⁹	With Primary Open-Angle Glaucoma With and Without Diabetes Mellitus. Optic Nerve Head Deformation in Glaucoma: The Temporal Relationship between Optic Nerve Head Surface Depression and Retinal Nerve Fiber Layer Thinning.	Ophthalmology.
Shin H-Y, Park H-YL, Park CK. ¹⁰	The effect of myopic optic disc tilt on measurement of spectral-domain optical coherence tomography parameters.	Br. J. Ophthalmol.
Mayama C, Tsutsumi T, Saito H, et al. ¹¹	Glaucoma-induced optic disc morphometric changes and glaucoma diagnostic ability of Heidelberg Retina Tomograph II in highly myopic eyes.	PloS One.
Rao HL, Yadav RK, Addepalli UK, et al. ¹²	The ISNT rule in glaucoma: revisiting with spectral domain optical coherence tomography.	Acta Ophthalmol. (Copenh.).
Hwang YH, Kim YY. ¹³	Application of the ISNT Rule to Neuroretinal Rim Thickness Determined Using Cirrus HD Optical Coherence Tomography.	J. Glaucoma.
Pradhan ZS, Braganza A, Abraham LM. ¹⁴	Does the ISNT Rule Apply to the Retinal Nerve Fiber Layer?	J. Glaucoma.
Field MG, Alasil T, Baniasadi N, et al. ¹⁵	Facilitating Glaucoma Diagnosis With Intereye Retinal Nerve Fiber Layer Asymmetry Using Spectral-Domain Optical Coherence Tomography.	J. Glaucoma.
Srinivasan S, Addepalli UK, Rao HL, Garudadri CS, Mandal AK. ¹⁶	Spectral domain optical coherence tomography in children operated for primary congenital glaucoma.	Br. J. Ophthalmol.
Ramli NM, Sidek S, Rahman FA, et al. ¹⁷	Novel use of 3T MRI in assessment of optic nerve volume in glaucoma.	Graefes Arch Clin Exp Ophthalmol.
Chen Z, Wang J, Lin F, et al. ¹⁸	Correlation between lateral geniculate nucleus atrophy and damage to the optic disc in glaucoma.	J. Neuroradiol.

Intraocular pressure

Rao HL, Yadav RK, Addepalli UK, et al. ¹⁹	Comparing Spectral-Domain Optical Coherence Tomography and Standard Automated Perimetry to Diagnose Glaucomatous Optic Neuropathy. Depth and area of retinal nerve fiber layer damage and visual field correlation analysis.	J. Glaucoma.
Suh W, Lee JM, Kee C. ²⁰	Correlation of retinal nerve fiber layer thickness and visual fields in glaucoma: a broken stick model.	Korean J. Ophthalmol.
Alasil T, Wang K, Yu F, et al. ²¹	Rates of retinal nerve fiber layer thinning in glaucoma suspect eyes.	Am. J. Ophthalmol.
Miki A, Medeiros FA, Weinreb RN, et al. ²²	Trabeculectomy Improves Vessel Response Measured by Dynamic Vessel Analysis (DVA) in Glaucoma Patients.	Ophthalmology.
Selbach JM, Schallenberg M, Kramer S, et al. ²³	Schlemm's canal expands after trabeculectomy in patients with primary angle-closure glaucoma.	Open Ophthalmol. J.
Hong J, Yang Y, Wei A, et al. ²⁴	The impact of structural and functional parameters in glaucoma patients on patient-reported visual functioning.	Invest. Ophthalmol. Vis. Sci.
Hirneiß C, Reznicek L, Vogel M, Pesudovs K. ²⁵	The relationship between visual field index and estimated number of retinal ganglion cells in glaucoma.	PloS One.
Marvasti AH, Tatham AJ, Zangwill LM, et al. ²⁶	Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma.	PloS One.
Medeiros FA, Lisboa R, Zangwill LM, et al. ²⁷		Ophthalmology.
Araci IE, Su B, Quake SR, Mandel Y. ²⁸	An implantable microfluidic device for self-monitoring of intraocular pressure.	Nat. Med.
Chen G-Z, Chan I-S, Leung LKK, Lam DCC. ²⁹	Soft wearable contact lens sensor for continuous intraocular pressure monitoring.	Med. Eng. Phys.
Åström S, Stenlund H, Lindén C. ³⁰	Intraocular pressure changes over 21 years - a longitudinal age-cohort study	Acta Ophthalmol. (Copenh.).

**Pharmacologic
intraocular pressure
lowering**

	in northern Sweden.	
Kim YJ, Sung KR, Lee KS, et al. ³¹	Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.	Am. J. Ophthalmol.
Bakri SJ, Moshfeghi DM, Francom S, et al. ³²	Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.	Ophthalmology.
Kim D, Nam WH, Kim HK, Yi K. ³³	Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?	J. Glaucoma.
Isobe T, Mizuno K, Kaneko Y, et al. ³⁴	Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys.	Curr. Eye Res.
Sumi K, Inoue Y, Nishio M, et al. ³⁵	Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.	Bioorg. Med. Chem. Lett.
Tanihara H, Inoue T, Yamamoto T, et al. ³⁶	Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.	JAMA Ophthalmol.
Tanihara H, Inoue T, Yamamoto T, et al. ³⁷	Double-masked, Randomized, Dose-Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure.	Am. J. Ophthalmol.
Bacharach J, Dubiner HB, Levy B, et al. ³⁸	The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.	Ophthalmology.
Ozyol E, Ozyol P. ³⁹		J. Glaucoma.

Corneal thickness and biomechanics

Khawaja AP, Chan MPY, Broadway DC, et al. ⁴⁰	Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study.	Ophthalmology.
Fedorchak MV, Conner IP, Medina CA, et al. ⁴¹	28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.	Exp. Eye Res.
Hirneiß C, Sekura K, Brandlhuber U, Kampik A, Kernt M. ⁴²	Corneal biomechanics predict the outcome of selective laser trabeculoplasty in medically uncontrolled glaucoma. Corneal Biomechanical Changes Following Trabeculectomy, Phaco-trabeculectomy, Ahmed Glaucoma Valve Implantation and Phacoemulsification.	Graefes Arch Clin Exp Ophthalmol.
Pakravan M, Afroozifar M, Yazdani S. ⁴³	Corneal viscoelastic differences between pseudoexfoliative glaucoma and primary open-angle glaucoma.	J. Ophthalmic Vis. Res.
Ozkok A, Tamcelik N, Ozdamar A, Sarici AM, Cicik E. ⁴⁴		J. Glaucoma.

Neuroprotection

Cheng H, Ding Y, Yu R, Chen J, Wu C. ⁴⁵	Neuroprotection of a novel cyclopeptide C*HSDGIC* from the cyclization of PACAP (1-5) in cellular and rodent models of retinal ganglion cell apoptosis.	PloS One.
You Y, Gupta VK, Li JC, et al. ⁴⁶	FTY720 protects retinal ganglion cells in experimental glaucoma.	Invest. Ophthalmol. Vis. Sci.
Xia X, Wen R, Chou T-H, et al. ⁴⁷	Protection of pattern electroretinogram and retinal ganglion cells by oncostatin M after optic nerve injury.	PloS One.
Tan P-P, Yuan H-H, Zhu X, et al. ⁴⁸	Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models.	CNS Neurosci. Ther.

Glaucoma laser therapy

Lee JW, Chan CW, Wong MO, et al. ⁴⁹	A randomized control trial to evaluate the effect of adjuvant selective laser trabeculoplasty versus medication alone in primary open-angle glaucoma: preliminary results.	Clin. Ophthalmol. Auckl. NZ.
Lee JWY, Gangwani RA, Chan JCH, Lai JSM. ⁵⁰	Prospective Study on the Efficacy of Treating Normal Tension Glaucoma With a Single Session of Selective Laser Trabeculoplasty.	J. Glaucoma.
Jinapriya D, D'Souza M, Hollands H, et al. ⁵¹	Anti-inflammatory Therapy after Selective Laser Trabeculoplasty: A Randomized, Double-Masked, Placebo-Controlled Clinical Trial.	Ophthalmology.
Susanna R, De Moraes CG, Alencar LM, Ritch R. ⁵²	Nd:YAG laser goniopuncture for late bleb failure after trabeculectomy with adjunctive mitomycin C.	JAMA Ophthalmol.

Glaucoma surgery: Trabeculectomy

Saheb H, Gedde SJ, Schiffman JC, Feuer WJ, Tube Versus Trabeculectomy Study Group. ⁵³	Outcomes of glaucoma reoperations in the Tube Versus Trabeculectomy (TVT) Study.	Am. J. Ophthalmol.
Yamada H, Sawada A, Kuwayama Y, Yamamoto T. ⁵⁴	Blindness following bleb-related infection in open angle glaucoma.	Jpn. J. Ophthalmol.
Schultz SK, Iverson SM, Shi W, Greenfield DS. ⁵⁵	Safety And Efficacy Of Achieving Single-Digit Intraocular Pressure Targets With Filtration Surgery In Eyes With Progressive Normal-Tension Glaucoma.	J. Glaucoma.

Glaucoma surgery: Implants

Christakis PG, Tsai JC, Kalenak JW, et al. ⁵⁶	The Ahmed versus Baerveldt study: three-year treatment outcomes.	Ophthalmology.
Chen G, Li W, Jiang F, Mao S, Tong Y. ⁵⁷	Ex-PRESS implantation versus trabeculectomy in open-angle glaucoma: a meta-analysis of	PloS One.

		randomized controlled clinical trials.	
		Meta-analysis of randomized controlled trials comparing EX-PRESS implantation with trabeculectomy for open-angle glaucoma.	PloS One.
	Wang W, Zhang X. ⁵⁸	Economic analysis of the Ex-PRESS miniature glaucoma device versus trabeculectomy.	J. Glaucoma.
	Patel HY, Wagschal LD, Trope GE, Buys YM. ⁵⁹		
Minimally invasive glaucoma surgery			
	Grover DS, Godfrey DG, Smith O, et al. ⁶⁰	Gonioscopy-assisted transluminal trabeculotomy, ab interno trabeculotomy: technique report and preliminary results.	Ophthalmology.
	Ahuja Y, Ma Khin Pyi S, Malihi M, Hodge DO, Sit AJ. ⁶¹	Clinical results of ab interno trabeculotomy using the trabectome for open-angle glaucoma: the Mayo Clinic series in Rochester, Minnesota.	Am. J. Ophthalmol.
	Iordanous Y, Kent JS, Hutnik CML, Malvankar-Mehta MS. ⁶²	Projected cost comparison of Trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan.	J. Glaucoma.
Secondary glaucoma			
	Osman EA, Mousa A, Al-Mansouri SM, Al-Mezaine HS. ⁶³	Glaucoma After Open-Globe Injury at a Tertiary Care University Hospital: Cumulative Causes and Management.	J. Glaucoma.
	Qian CX, Hassanaly S, Harissi-Dagher M. ⁶⁴	Anterior Segment Optical Coherence Tomography in the Long-Term Follow-up and Detection of Glaucoma in Boston Type I Keratoprosthesis.	Ophthalmology.
	Cunha-Vaz J, Ashton P, Iezzi R, et al. ⁶⁵	Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.	Ophthalmology.

Glaucoma Genetics

Chen Y, Lin Y, Vithana EN, et al. ⁶⁶	Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma.	Nat. Genet.
Gharahkhani P, Burdon KP, Fogarty R, et al. ⁶⁷	Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma.	Nat. Genet.
Hysi PG, Cheng C-Y, Springelkamp H, et al. ⁶⁸	Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma.	Nat. Genet.
Anastasopoulos E, Coleman AL, Wilson MR, et al. ⁶⁹	Association of LOXL1 polymorphisms with pseudoexfoliation, glaucoma, intraocular pressure, and systemic diseases in a Greek population. The Thessaloniki eye study.	Invest. Ophthalmol. Vis. Sci.

Glaucoma morbidity

Malihi M, Moura Filho ER, Hodge DO, Sit AJ. ⁷⁰	Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota.	Ophthalmology.
Kim M, Jeoung JW, Park KH, et al. ⁷¹	Metabolic syndrome as a risk factor in normal-tension glaucoma.	Acta Ophthalmol. (Copenh.).
Tzu JH, Shah CT, Galor A, et al. ⁷²	Refractive Outcomes of Combined Cataract and Glaucoma Surgery.	J. Glaucoma.

References

1. Rao HL, Yadav RK, Begum VU, et al. Role of visual field reliability indices in ruling out glaucoma. *JAMA Ophthalmol.* 2015;133(1):40–44.
2. Musch DC, Gillespie BW, Palmberg PF, et al. Visual field improvement in the collaborative initial glaucoma treatment study. *Am. J. Ophthalmol.* 2014;158(1):96–104.e2.
3. Liu S, Yu M, Weinreb RN, et al. Frequency doubling technology perimetry for detection of visual field progression in glaucoma: a pointwise linear regression analysis. *Invest. Ophthalmol. Vis. Sci.* 2014;55(5):2862–2869.

4. Meira-Freitas D, Tatham AJ, Lisboa R, et al. Predicting progression of glaucoma from rates of frequency doubling technology perimetry change. *Ophthalmology*. 2014;121(2):498–507.
5. Prokosch V, Eter N. Correlation between early retinal nerve fiber layer loss and visual field loss determined by three different perimetric strategies: white-on-white, frequency-doubling, or flicker-defined form perimetry. *Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol.* 2014;252(10):1599–1606.
6. Hata M, Miyamoto K, Oishi A, et al. Comparison of Optic Disc Morphology of Optic Nerve Atrophy between Compressive Optic Neuropathy and Glaucomatous Optic Neuropathy. *PloS One*. 2014;9(11):e112403.
7. Danesh-Meyer HV, Yap J, Frampton C, Savino PJ. Differentiation of compressive from glaucomatous optic neuropathy with spectral-domain optical coherence tomography. *Ophthalmology*. 2014;121(8):1516–1523.
8. Akkaya S, Can E, Oztürk F. Comparison of Optic Nerve Head Topographic Parameters in Patients With Primary Open-Angle Glaucoma With and Without Diabetes Mellitus. *J. Glaucoma*. 2014.
9. Xu G, Weinreb RN, Leung CKS. Optic Nerve Head Deformation in Glaucoma: The Temporal Relationship between Optic Nerve Head Surface Depression and Retinal Nerve Fiber Layer Thinning. *Ophthalmology*. 2014;121(12):2362–2370.
10. Shin H-Y, Park H-YL, Park CK. The effect of myopic optic disc tilt on measurement of spectral-domain optical coherence tomography parameters. *Br. J. Ophthalmol.* 2015;99(1):69–74.
11. Mayama C, Tsutsumi T, Saito H, et al. Glaucoma-induced optic disc morphometric changes and glaucoma diagnostic ability of Heidelberg Retina Tomograph II in highly myopic eyes. *PloS One*. 2014;9(1):e86417.
12. Rao HL, Yadav RK, Addepalli UK, et al. The ISNT rule in glaucoma: revisiting with spectral domain optical coherence tomography. *Acta Ophthalmol. (Copenh.)*. 2014.
13. Hwang YH, Kim YY. Application of the ISNT Rule to Neuroretinal Rim Thickness Determined Using Cirrus HD Optical Coherence Tomography. *J. Glaucoma*. 2013.
14. Pradhan ZS, Braganza A, Abraham LM. Does the ISNT Rule Apply to the Retinal Nerve Fiber Layer? *J. Glaucoma*. 2014.

15. Field MG, Alasil T, Baniasadi N, et al. Facilitating Glaucoma Diagnosis With Intereye Retinal Nerve Fiber Layer Asymmetry Using Spectral-Domain Optical Coherence Tomography. *J. Glaucoma*. 2014.
16. Srinivasan S, Addepalli UK, Rao HL, Garudadri CS, Mandal AK. Spectral domain optical coherence tomography in children operated for primary congenital glaucoma. *Br. J. Ophthalmol*. 2014;98(2):162–165.
17. Ramli NM, Sidek S, Rahman FA, et al. Novel use of 3T MRI in assessment of optic nerve volume in glaucoma. *Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol*. 2014;252(6):995–1000.
18. Chen Z, Wang J, Lin F, et al. Correlation between lateral geniculate nucleus atrophy and damage to the optic disc in glaucoma. *J. Neuroradiol. J. Neuroradiol*. 2013;40(4):281–287.
19. Rao HL, Yadav RK, Addepalli UK, et al. Comparing Spectral-Domain Optical Coherence Tomography and Standard Automated Perimetry to Diagnose Glaucomatous Optic Neuropathy. *J. Glaucoma*. 2014.
20. Suh W, Lee JM, Kee C. Depth and area of retinal nerve fiber layer damage and visual field correlation analysis. *Korean J. Ophthalmol. KJO*. 2014;28(4):323–329.
21. Alasil T, Wang K, Yu F, et al. Correlation of retinal nerve fiber layer thickness and visual fields in glaucoma: a broken stick model. *Am. J. Ophthalmol*. 2014;157(5):953–959.
22. Miki A, Medeiros FA, Weinreb RN, et al. Rates of retinal nerve fiber layer thinning in glaucoma suspect eyes. *Ophthalmology*. 2014;121(7):1350–1358.
23. Selbach JM, Schallenberg M, Kramer S, et al. Trabeculectomy Improves Vessel Response Measured by Dynamic Vessel Analysis (DVA) in Glaucoma Patients. *Open Ophthalmol. J*. 2014;8:75–81.
24. Hong J, Yang Y, Wei A, et al. Schlemm's canal expands after trabeculectomy in patients with primary angle-closure glaucoma. *Invest. Ophthalmol. Vis. Sci*. 2014;55(9):5637–5642.
25. Hirneiß C, Reznicek L, Vogel M, Pesudovs K. The impact of structural and functional parameters in glaucoma patients on patient-reported visual functioning. *PloS One*. 2013;8(12):e80757.

26. Marvasti AH, Tatham AJ, Zangwill LM, et al. The relationship between visual field index and estimated number of retinal ganglion cells in glaucoma. *PloS One*. 2013;8(10):e76590.
27. Medeiros FA, Lisboa R, Zangwill LM, et al. Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma. *Ophthalmology*. 2014;121(1):100–109.
28. Araci IE, Su B, Quake SR, Mandel Y. An implantable microfluidic device for self-monitoring of intraocular pressure. *Nat. Med*. 2014;20(9):1074–1078.
29. Chen G-Z, Chan I-S, Leung LKK, Lam DCC. Soft wearable contact lens sensor for continuous intraocular pressure monitoring. *Med. Eng. Phys*. 2014;36(9):1134–1139.
30. Åström S, Stenlund H, Lindén C. Intraocular pressure changes over 21 years - a longitudinal age-cohort study in northern Sweden. *Acta Ophthalmol. (Copenh.)*. 2014;92(5):417–420.
31. Kim YJ, Sung KR, Lee KS, et al. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. *Am. J. Ophthalmol*. 2014;157(6):1266–1271.e1.
32. Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. *Ophthalmology*. 2014;121(5):1102–1108.
33. Kim D, Nam WH, Kim HK, Yi K. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure? *J. Glaucoma*. 2014;23(7):446–448.
34. Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. *Curr. Eye Res*. 2014;39(8):813–822.
35. Sumi K, Inoue Y, Nishio M, et al. IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys. *Bioorg. Med. Chem. Lett*. 2014;24(3):831–834.
36. Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. *JAMA Ophthalmol*. 2013;131(10):1288–1295.

37. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. *Am. J. Ophthalmol.* 2013;156(4):731–736.
38. Bacharach J, Dubiner HB, Levy B, et al. Double-masked, Randomized, Dose-Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure. *Ophthalmology.* 2015;122(2):302–307.
39. Ozyol E, Ozyol P. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure. *J. Glaucoma.* 2014.
40. Khawaja AP, Chan MPY, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. *Ophthalmology.* 2014;121(8):1501–1507.
41. Fedorchak MV, Conner IP, Medina CA, et al. 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres. *Exp. Eye Res.* 2014;125:210–216.
42. Hirneiß C, Sekura K, Brandlhuber U, Kampik A, Kernt M. Corneal biomechanics predict the outcome of selective laser trabeculoplasty in medically uncontrolled glaucoma. *Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol.* 2013;251(10):2383–2388.
43. Pakravan M, Afroozifar M, Yazdani S. Corneal Biomechanical Changes Following Trabeculectomy, Phaco-trabeculectomy, Ahmed Glaucoma Valve Implantation and Phacoemulsification. *J. Ophthalmic Vis. Res.* 2014;9(1):7–13.
44. Ozkok A, Tamcelik N, Ozdamar A, Sarici AM, Cicik E. Corneal viscoelastic differences between pseudoexfoliative glaucoma and primary open-angle glaucoma. *J. Glaucoma.* 2013;22(9):740–745.
45. Cheng H, Ding Y, Yu R, Chen J, Wu C. Neuroprotection of a novel cyclopeptide C*HSDGIC* from the cyclization of PACAP (1-5) in cellular and rodent models of retinal ganglion cell apoptosis. *PloS One.* 2014;9(10):e108090.
46. You Y, Gupta VK, Li JC, et al. FTY720 protects retinal ganglion cells in experimental glaucoma. *Invest. Ophthalmol. Vis. Sci.* 2014;55(5):3060–3066.

47. Xia X, Wen R, Chou T-H, et al. Protection of pattern electroretinogram and retinal ganglion cells by oncostatin M after optic nerve injury. *PloS One*. 2014;9(9):e108524.
48. Tan P-P, Yuan H-H, Zhu X, et al. Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models. *CNS Neurosci. Ther.* 2014;20(3):227–236.
49. Lee JW, Chan CW, Wong MO, et al. A randomized control trial to evaluate the effect of adjuvant selective laser trabeculoplasty versus medication alone in primary open-angle glaucoma: preliminary results. *Clin. Ophthalmol. Auckl. NZ.* 2014;8:1987–1992.
50. Lee JWY, Gangwani RA, Chan JCH, Lai JSM. Prospective Study on the Efficacy of Treating Normal Tension Glaucoma With a Single Session of Selective Laser Trabeculoplasty. *J. Glaucoma*. 2014.
51. Jinapriya D, D’Souza M, Hollands H, et al. Anti-inflammatory Therapy after Selective Laser Trabeculoplasty: A Randomized, Double-Masked, Placebo-Controlled Clinical Trial. *Ophthalmology*. 2014;121(12):2356–2361.
52. Susanna R, De Moraes CG, Alencar LM, Ritch R. Nd:YAG laser goniopuncture for late bleb failure after trabeculectomy with adjunctive mitomycin C. *JAMA Ophthalmol.* 2014;132(3):286–290.
53. Saheb H, Gedde SJ, Schiffman JC, Feuer WJ, Tube Versus Trabeculectomy Study Group. Outcomes of glaucoma reoperations in the Tube Versus Trabeculectomy (TVT) Study. *Am. J. Ophthalmol.* 2014;157(6):1179–1189.e2.
54. Yamada H, Sawada A, Kuwayama Y, Yamamoto T. Blindness following bleb-related infection in open angle glaucoma. *Jpn. J. Ophthalmol.* 2014;58(6):490–495.
55. Schultz SK, Iverson SM, Shi W, Greenfield DS. Safety And Efficacy Of Achieving Single-Digit Intraocular Pressure Targets With Filtration Surgery In Eyes With Progressive Normal-Tension Glaucoma. *J. Glaucoma*. 2014.
56. Christakis PG, Tsai JC, Kalenak JW, et al. The Ahmed versus Baerveldt study: three-year treatment outcomes. *Ophthalmology*. 2013;120(11):2232–2240.
57. Chen G, Li W, Jiang F, Mao S, Tong Y. Ex-PRESS implantation versus trabeculectomy in open-angle glaucoma: a meta-analysis of randomized controlled clinical trials. *PloS One*. 2014;9(1):e86045.

58. Wang W, Zhang X. Meta-analysis of randomized controlled trials comparing EX-PRESS implantation with trabeculectomy for open-angle glaucoma. *PloS One*. 2014;9(6):e100578.
59. Patel HY, Wagschal LD, Trope GE, Buys YM. Economic analysis of the Ex-PRESS miniature glaucoma device versus trabeculectomy. *J. Glaucoma*. 2014;23(6):385–390.
60. Grover DS, Godfrey DG, Smith O, et al. Gonioscopy-assisted transluminal trabeculotomy, ab interno trabeculotomy: technique report and preliminary results. *Ophthalmology*. 2014;121(4):855–861.
61. Ahuja Y, Ma Khin Pyi S, Malihi M, Hodge DO, Sit AJ. Clinical results of ab interno trabeculotomy using the trabectome for open-angle glaucoma: the Mayo Clinic series in Rochester, Minnesota. *Am. J. Ophthalmol*. 2013;156(5):927–935.e2.
62. Iordanous Y, Kent JS, Hutnik CML, Malvankar-Mehta MS. Projected cost comparison of Trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan. *J. Glaucoma*. 2014;23(2):e112–118.
63. Osman EA, Mousa A, Al-Mansouri SM, Al-Mezaine HS. Glaucoma After Open-Globe Injury at a Tertiary Care University Hospital: Cumulative Causes and Management. *J. Glaucoma*. 2014.
64. Qian CX, Hassanaly S, Harissi-Dagher M. Anterior Segment Optical Coherence Tomography in the Long-Term Follow-up and Detection of Glaucoma in Boston Type I Keratoprosthesis. *Ophthalmology*. 2015;122(2):317–325.
65. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. *Ophthalmology*. 2014;121(10):1892–1903.
66. Chen Y, Lin Y, Vithana EN, et al. Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma. *Nat. Genet*. 2014;46(10):1115–1119.
67. Gharahkhani P, Burdon KP, Fogarty R, et al. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. *Nat. Genet*. 2014;46(10):1120–1125.
68. Hysi PG, Cheng C-Y, Springelkamp H, et al. Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. *Nat. Genet*. 2014;46(10):1126–1130.

69. Anastasopoulos E, Coleman AL, Wilson MR, et al. Association of LOXL1 polymorphisms with pseudoexfoliation, glaucoma, intraocular pressure, and systemic diseases in a Greek population. The Thessaloniki eye study. *Invest. Ophthalmol. Vis. Sci.* 2014;55(7):4238–4243.
70. Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. *Ophthalmology.* 2014;121(1):134–141.
71. Kim M, Jeoung JW, Park KH, et al. Metabolic syndrome as a risk factor in normal-tension glaucoma. *Acta Ophthalmol. (Copenh.).* 2014;92(8):e637–643.
72. Tzu JH, Shah CT, Galor A, et al. Refractive Outcomes of Combined Cataract and Glaucoma Surgery. *J. Glaucoma.* 2013.